Reuters logo
BRIEF-Galectin Therapeutics updates on completion of Nash Cx trial
June 13, 2017 / 12:40 PM / 3 months ago

BRIEF-Galectin Therapeutics updates on completion of Nash Cx trial

June 13 (Reuters) - Galectin Therapeutics Inc:

* Galectin therapeutics announces important milestones towards completion of Nash Cx trial

* As of time of their evaluation, therapy had been completed in 68% of subjects in Nash-Cx trial​

* ‍Independent data safety monitoring board recently concluded from safety perspective, company’s Nash-Cx trial should continue​

* ‍Panel recently met to review safety data of all enrolled subjects who had completed trial​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below